Long-term Results of Ligation of Patent Ductus Arteriosus in Premature Infants.
10.4326/jjcvs.21.35
- VernacularTitle:未熟児ＰＤＡ結さつ術の遠隔成績
- Author:
Tohru SAKURADA
;
Ryosei KURIBAYASHI
;
Satoshi SEKINE
;
Hiroaki AIDA
;
Keiji SEKI
;
Yoshikazu GOTO
;
Yoshiki SHIBATA
;
Atsushi MEGURO
;
Ryuji HAYASHI
;
Tadaaki ABE
- Publication Type:Journal Article
- Keywords:
bronchopulmonary dysplasia
- From:Japanese Journal of Cardiovascular Surgery
1992;21(1):35-40
- CountryJapan
- Language:Japanese
-
Abstract:
From January 1979 through May 1982, 36 premature infants less than 2.5kg and less than 35 weeks of gestation, including 24 patients with respiratory distress syndrome, underwent ligation of patent ductus arteriosus (PDA) due to being unresponsive to medical treatment. Ten patients died postoperatively mainly from intracranial hemorrhage and necrotizing enterocolitis. Surviving 26 patients were examined for developmental sequelae based on questionnaire survey. One infant died of respiratory failure secondary to severe bronchopulmonary dysplasia 28th month after operation. We found no evidence of recurrent ductal patency following ligation during the follow-up period. Twenty four patients exhibited normal motor and mental development to attend the ordinary elementary school everyday, but one patient shows mental retardation. Most of patients suffered from the frequent upper respiratory infection in childhood to require rehospitalization. There are no patients with hoarseness, but 2 patients developed funnel chest and one required the operation. One third of the patients had ophthalmological handicap (myopia or strabismus). Surgical ligation of PDA in premature infants seems to reduce the duration of postoperative mechanical ventilation and the incidence of bronchopulmonary dysplasia. Analyzing long-term follow-up indicates that infants who undergo PDA ligation grow almost normally and do not appear to be at increased risk for sensorineural handicaps. Therefore we emphasize that surgical ligation of PDA is an effective and appropriate treatment of choice for significant PDA in premature infants.
